Oncimmune (LON:ONC) Trading Down 14.4% – What’s Next?

Shares of Oncimmune Holdings plc (LON:ONC) fell 14.4% on Monday . The stock traded as low as GBX 1.27 ($0.02) and last traded at GBX 1.27 ($0.02). 127,956 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 602,695 shares. The stock had previously closed at GBX 1.48 ($0.02).

Oncimmune Stock Performance

The stock has a market cap of £1.44 million, a price-to-earnings ratio of 0.14 and a beta of 1.19. The company has a current ratio of 1.14, a quick ratio of 0.63 and a debt-to-equity ratio of -412.06. The firm has a fifty day simple moving average of GBX 8.89 and a 200-day simple moving average of GBX 13.80.

Oncimmune (LON:ONC) last issued its quarterly earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter. Oncimmune had a net margin of 581.63% and a negative return on equity of 2,277.74%.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.